InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,973.10
(
0.74%
)
US TECH 100
20,544.40
(
1.59%
)
Dow Jones
43,729.34
(
0.00%
)
Brent Oil
75.00
(
-0.62%
)
Bitcoin
75,787.32
(
-0.15%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120687
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 09/03/2007 6:08:49 PM

Monday, September 03, 2007 6:08:49 PM

Post# of 19309
How likely is the U.S. ATryn trial to succeed?

[Reposted from msg #4576 with typographical corrections.]


Success is likely, IMO, for several reasons:

1. The unmet medical need for ATryn in the U.S. is much greater than in Europe because there is only one approved plasma-derived antithrombin product (Thrombate from Talecris) and its supply is small and unreliable (#msg-20966468). By comparison, Europe has a reliable source of plasma-derived antithrombin from several manufacturers.

2. Compared to the phase-3 trial that got ATryn approved in Europe, the U.S. phase-3 trial includes more than twice as many patients treated with ATryn and it has a control arm (#msg-5609005).

3. Forty-five percent (14/31) of the patients in the ATryn arm of the U.S. phase-3 trial are already known to have been treated successfully because they are the same 14 patients who comprised the data set that led to ATryn approval in the EU. This is like a baseball player stepping up to home plate with a count of two balls and no strikes!

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up